<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="publisher-id">jbpneu</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26785966</article-id>
      <article-id pub-id-type="pmc">4723008</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37562015000000299</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of S&#xE3;o Paulo, Brazil: a report of three cases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Arbex</surname>
            <given-names>Marcos Abdo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Siqueira</surname>
            <given-names>H&#xE9;lio Ribeiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>D'Ambrosio</surname>
            <given-names>Lia</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
          <xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Migliori</surname>
            <given-names>Giovanni Battista</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>. Hospital Nestor Goulart Reis, Secretaria de Estado da Sa&#xFA;de do Estado de S&#xE3;o Paulo, Am&#xE9;rico Brasiliense (SP) Brasil. </aff>
      <aff id="aff2"><label>2</label>. Curso de Medicina, Centro Universit&#xE1;rio de Araraquara, Araraquara (SP) Brasil. </aff>
      <aff id="aff3"><label>3</label>. Disciplina de Pneumologia e Tisiologia, Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro (RJ) Brasil. </aff>
      <aff id="aff4"><label>4</label>. Ambulat&#xF3;rio de Tuberculose, Hospital Universit&#xE1;rio Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro (RJ) Brasil. </aff>
      <aff id="aff5"><label>5</label>. WHO Collaborating Centre for TB and Lung Diseases, Istituto Scientifico, Fondazione Salvatore Maugeri, Tradate, Italia. </aff>
      <aff id="aff6"><label>6</label>. Public Health Consulting Group, Lugano, Switzerland. </aff>
      <author-notes>
        <corresp id="c1">Correspondence to: Marcos Abdo Arbex. Rua Volunt&#xE1;rios da P&#xE1;tria, 2104, CEP 14801-320, Araraquara, SP, Brasil. Tel.: 55 16 99714-2882. Fax: 55 16 3333-7788. E-mail: <email>arbexma@techs.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Nov-Dec</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2015</year>
      </pub-date>
      <volume>41</volume>
      <issue>6</issue>
      <fpage>554</fpage>
      <lpage>559</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>9</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>Here, we report the cases of three patients diagnosed with extensively drug-resistant tuberculosis and admitted to a referral hospital in the state of S&#xE3;o Paulo, Brazil, showing the clinical and radiological evolution, as well as laboratory test results, over a one-year period. Treatment was based on the World Health Organization guidelines, with the inclusion of a new proposal for the use of a combination of antituberculosis drugs (imipenem and linezolid). In the cases studied, we show the challenge of creating an acceptable, effective treatment regimen including drugs that are more toxic, are more expensive, and are administered for longer periods. We also show that treatment costs are significantly higher for such patients, which could have an impact on health care systems, even after hospital discharge. We highlight the fact that in extreme cases, such as those reported here, hospitalization at a referral center seems to be the most effective strategy for providing appropriate treatment and increasing the chance of cure. In conclusion, health professionals and governments must make every effort to prevent cases of multidrug-resistant and extensively drug-resistant tuberculosis. </p>
      </abstract>
      <kwd-group>
        <title>Keywords:</title>
        <kwd>Tuberculosis, multidrug-resistant</kwd>
        <kwd>Extensively drug-resistant tuberculosis</kwd>
        <kwd>Antitubercular agents</kwd>
        <kwd>Antibiotics, antitubercular</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="6"/>
        <equation-count count="0"/>
        <ref-count count="14"/>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The number of cases of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has increased significantly, MDR-TB and XDR-TB having become a serious public health problem worldwide. Recent data show that the number of cases of MDR-TB tripled between 2009 and 2013.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> In 2013, cases of MDR-TB accounted for 3.5% of all new tuberculosis cases and 20.5% of all previously treated tuberculosis cases. Cases of XDR-TB accounted for 9% of all MDR-TB cases reported in 100 countries.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> MDR-TB is caused by <italic>Mycobacterium tuberculosis </italic> strains that are resistant to rifampin and isoniazid, whereas XDR-TB is caused by strains that are also resistant to any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, kanamycin, and capreomycin).<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>-</sup>
<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref> The increasing recognition of MDR-TB and XDR-TB has led to the development of new therapeutic strategies combining standard and new antituberculosis drugs. The World Health Organization (WHO) has divided first-line drugs (which are more effective), second-line drugs (which are less effective, are more toxic, and require longer treatment duration), and additional drugs for reinforcement (the use of which depends on their efficacy and tolerability) into five groups.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B5" ref-type="bibr">
<sup>5</sup>
</xref>
<xref ref-type="table" rid="t1">Table 1</xref> shows the five groups of drugs and the WHO recommendations for their use. </p>
      <p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Antituberculosis drug groups proposed by the World Health Organization and step-by-step recommendations for creating a treatment regimen for patients with multidrug-resistant or extensively drug-resistant tuberculosis. </title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Groups</th><th align="center" rowspan="1" colspan="1">Drugs</th><th align="center" rowspan="1" colspan="1">Steps</th><th align="center" rowspan="1" colspan="1">What to do</th><th align="center" rowspan="1" colspan="1">Drugs to consider</th><th align="center" rowspan="1" colspan="1">Notes</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">First-line oral drugs &#x2022; Isoniazid &#x2022; Rifampin &#x2022; Ethambutol &#x2022; Pyrazinamide &#x2022; Rifabutin &#x2022; Rifapentine</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Choose an injectable (group 2) drug on the basis of drug susceptibility test results or patient history of tuberculosis treatment.</td><td align="center" rowspan="1" colspan="1">amikacin, capreomycin, and kanamycin</td><td align="center" rowspan="1" colspan="1">Streptomycin is not generally used, because MDR-TB is highly resistant to it.</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Injectable drugs &#x2022; Streptomycin &#x2022; Kanamycin &#x2022; Amikacin &#x2022; Capreomycin</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Choose a next-generation fluoroquinolone (group 3).</td><td align="center" rowspan="1" colspan="1">levofloxacin and moxifloxacin</td><td align="center" rowspan="1" colspan="1">In case of resistance to levofloxacin, moxifloxacin should be used. Moxifloxacin should be avoided in case bedaquiline is used.</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Fluoroquinolones &#x2022; Levofloxacin &#x2022; Moxifloxacin &#x2022; Gatifloxacin</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Add two or more group 4 drugs.</td><td align="center" rowspan="1" colspan="1">cycloserine, terizidone, para-aminosalicylic acid, ethionamide, and prothionamide</td><td align="center" rowspan="1" colspan="1">Ethionamide and prothionamide are the most effective group 4 drugs. Patient history of tuberculosis treatment, side effects, and cost should be taken into consideration. In general, drug susceptibility testing does not include group 3 drugs.</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Oral second-line drugs &#x2022; Ethionamide &#x2022; Prothionamide &#x2022; Cycloserine &#x2022; Terizidone &#x2022; Para-aminosalicylic acid &#x2022; Sodium aminosalicylate</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Add group 1 drugs.</td><td align="center" rowspan="1" colspan="1">pyrazinamide and ethambutol</td><td align="center" rowspan="1" colspan="1">Pyrazinamide is commonly used in most treatment regimens. Ethambutol is used on the basis of susceptibility test results.</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Additional drugs for reinforcement &#x2022; Linezolid &#x2022; Ertapenem &#x2022; Imipenem/cilastatin &#x2022; Meropenem &#x2022; Clarithromycin &#x2022; Thiacetazone &#x2022; Amoxicillin/clavulanate &#x2022; Clofazimine &#x2022; High-dose isoniazid (has a modest effect) &#x2022; Bedaquiline &#x2022; Delamanid</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Consider the possibility of adding group 5 drugs in case it is impossible to use 4 effective group 2-3-4 drugs.</td><td align="center" rowspan="1" colspan="1">bedaquiline, linezolid, clofazimine, amoxicillin/clavulanate, ertapenem, imipenem/cilastatin + clavulanate, meropenem + clavulanate, high-dose isoniazid, clarithromycin, and thiacetazone</td><td align="center" rowspan="1" colspan="1">If necessary, 2 or more group 5 drugs can be used. It should be noted that there are no standardized susceptibility tests for group 5 drugs.</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Adapted from the World Health Organization<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> and Zumla et al.<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref> MDR-TB: multidrug-resistant tuberculosis. </p></fn></table-wrap-foot></table-wrap>
</p>
      <p>A standard or an individualized approach can be used in order to treat patients with MDR-TB. Official agencies recommend standard treatment regimens on the basis of health data (e.g., resistance patterns) in a given region.<xref rid="B2" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>,</sup>
<xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref> In Brazil, the treatment of MDR-TB is standardized by the National Ministry of Health.<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref> The WHO<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> recommends that the treatment of MDR-TB be divided into two phases: the intensive phase and the maintenance phase. In the intensive phase, which lasts 8 months, at least four potentially effective drugs should be used: an injectable drug (group 2), a fluoroquinolone (group 3), an oral drug (group 4), and an additional drug for reinforcement (group 5). In the maintenance phase, the injectable drug is discontinued, and the remaining drugs should be continued for 12 months after a negative sputum culture.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref> However, according to some authors, MDR-TB treatment should continue for at least 20 months. Recent studies have shown that continuing treatment for 18 months after a negative sputum culture prevents treatment failure, recurrence, and mortality.<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>-</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</p>
      <p>The treatment of XDR-TB should be individualized on the basis of patient history of tuberculosis treatment and patterns of resistance to first- and second-line drugs. <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref> For patients with XDR-TB, the WHO<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> recommends special precautions: the use of pyrazinamide and/or another group 1 drug; the use of next-generation quinolones (moxifloxacin or gatifloxacin) even if drug susceptibility test results show resistance to levofloxacin, ofloxacin, or both; whenever possible, the use of the injectable antituberculosis agent (aminoglycoside or capreomycin) to which the bacterial sample is susceptible, which should continue for 12 months or even for the duration of the treatment; the use of two or more group 5 drugs; and the use of all group 4 drugs that have not been extensively prescribed or that are considered effective. </p>
      <p>The objective of the present study was to show the 1-year progression of three XDR-TB patients admitted to <italic>Hospital Nestor Goulart Reis </italic> (HNGR), which is located in the city of Am&#xE9;rico Brasiliense, Brazil, and is a S&#xE3;o Paulo State Department of Health referral hospital for the treatment of MDR-TB and XDR-TB patients requiring hospitalization. </p>
    </sec>
    <sec>
      <title>CASE REPORTS</title>
      <p>Below, we describe the cases of three patients who were admitted to and treated at our institution. Preadmission treatment regimens and drug susceptibility test results for the three patients (herein identified as patient 1, patient 2, and patient 3) are presented in <xref ref-type="table" rid="t2">Table 2</xref>, whereas postadmission treatment regimens, drug susceptibility test results, body weight, smear microscopy results, results of culture for Koch's bacillus, erythrocyte sedimentation rate (ESR), and C-reactive protein are presented in <xref ref-type="table" rid="t3">Table 3</xref>. </p>
      <p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Treatment setting, duration, regimen, and outcome, as well as drug susceptibility test results, for the three patients in the present study prior to their admission to <italic>Hospital Nestor Goulart Reis </italic>, located in the city of Am&#xE9;rico Brasiliense, Brazil. </title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="2"/><col span="1"/><col span="1"/><col span="1"/><col span="3"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Treatment setting</th><th align="center" rowspan="2" colspan="1">Drug susceptibility testing</th><th align="center" rowspan="2" colspan="1">Treatment duration (from month/year to month/year)</th><th align="center" colspan="2" rowspan="1">Treatment regimen </th><th align="center" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">
</th><th align="center" colspan="3" rowspan="1">Treatment outcome </th><th align="center" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">
</th></tr><tr><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">H</th><th align="center" rowspan="1" colspan="1">Z</th><th align="center" rowspan="1" colspan="1">E</th><th align="center" rowspan="1" colspan="1">S</th><th align="center" rowspan="1" colspan="1">Et</th><th align="center" rowspan="1" colspan="1">O</th><th align="center" rowspan="1" colspan="1">T</th><th align="center" rowspan="1" colspan="1">C</th><th align="center" rowspan="1" colspan="1">v</th><th align="center" rowspan="1" colspan="1">L</th><th align="left" rowspan="1" colspan="1">
</th></tr><tr><th align="center" rowspan="1" colspan="1">Patient 1</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th><th align="left" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,E,S)</td><td align="center" rowspan="1" colspan="1">05/2001-11/2001</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Failure</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,E,Z,S)</td><td align="center" rowspan="1" colspan="1">01/2003-07/2003</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Nonadherence</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,Z)</td><td align="center" rowspan="1" colspan="1">09/2005-09/2007</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Nonadherence</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,Z); Susceptibility to (E,S)</td><td align="center" rowspan="1" colspan="1">11/2007-07/2008</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Nonadherence</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,E,Z)</td><td align="center" rowspan="1" colspan="1">08/2008-09/2010</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Nonadherence</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,E,Z,S)</td><td align="center" rowspan="1" colspan="1">06/2011-10/2011</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Referral for hospitalization (at <italic>Sanatorinhos </italic>, in the city of Campos do Jord&#xE3;o, Brazil)</td></tr><tr><td align="left" rowspan="1" colspan="1">Inpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (A,C,K,S,E,H,O,Z,R)</td><td align="center" rowspan="1" colspan="1">10/2011-03/2013</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Disciplinary discharge</td></tr><tr><td align="left" rowspan="1" colspan="1">Inpatient (HNGR)</td><td align="left" rowspan="1" colspan="1">Resistance to (A,C,S,H,O,Z,R); Susceptibility to (E)</td><td align="center" rowspan="1" colspan="1">03/2013-08/2013</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Failure</td></tr><tr><td align="center" rowspan="1" colspan="1">Patient 2</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">03/2011-10/2011</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Failure</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,Z,O); Susceptibility to (A,K,Cp,S,E)</td><td align="center" rowspan="1" colspan="1">03/2012-10/2013</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Failure</td></tr><tr><td align="center" rowspan="1" colspan="1">Patient 3</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">01/2006-05/2006</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Nonadherence</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H); Susceptibility to (Z,E,S,Et)</td><td align="center" rowspan="1" colspan="1">06/2006-06/2007</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Nonadherence</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H); Susceptibility to (Z,E,S,Et)</td><td align="center" rowspan="1" colspan="1">08/2007-07/2009</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Cure</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H); Susceptibility to (Z,E,S)</td><td align="center" rowspan="1" colspan="1">09/2009-04/2010</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">X</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">Failure</td></tr><tr><td align="left" rowspan="1" colspan="1">Inpatient (at <italic>Sanatorinhos </italic>, in the city of Campos do Jord&#xE3;o, Brazil)</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,S); Susceptibility to (Z,E)</td><td align="center" rowspan="1" colspan="1">04/2010-03/2012</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1">Failure</td></tr><tr><td align="left" rowspan="1" colspan="1">Outpatient</td><td align="left" rowspan="1" colspan="1">Resistance to (R,H,S); Susceptibility to (Z,E)</td><td align="center" rowspan="1" colspan="1">02/2013-02/2014</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Failure</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>R: rifampin; H: isoniazid; Z: pyrazinamide; E: ethambutol; S: streptomycin; Et: ethionamide; O: ofloxacin; T: terizidone; C: clofazimine; A: amikacin; L: levofloxacin; K: kanamycin; Cp: capreomycin; and HNGR: <italic>Hospital Nestor Goulart Reis </italic>.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>
<table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Drug susceptibility test results, treatment regimen, body weight, erythrocyte sedimentation rate (ESR), C-reactive protein, sputum smear microscopy, and culture for Koch's bacillus over a one-year period for the three patients studied. </title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">Drug susceptibility testing</th><th align="center" rowspan="1" colspan="1">Treatment regimen</th><th align="center" rowspan="1" colspan="1">Treatment duration</th><th align="center" rowspan="1" colspan="1">Month</th><th align="center" rowspan="1" colspan="1">Weight. kg</th><th align="center" rowspan="1" colspan="1">ESR. mm/h</th><th align="center" rowspan="1" colspan="1">CRP. mg/l</th><th align="center" rowspan="1" colspan="1">Culture</th><th align="center" rowspan="1" colspan="1">Sputum smear microscopy</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Resistance to (A,Cp,K,S,E, H,O,Z,R)</td><td align="left" rowspan="1" colspan="1">A (Mon-Fri)+M+ E+T+Et+Lz+I+ Clr+Clv</td><td align="left" rowspan="1" colspan="1">09/2013-09/2014</td><td align="center" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">55.00</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">31.6</td><td align="center" rowspan="1" colspan="1">positive</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">54.15</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">6.7</td><td align="center" rowspan="1" colspan="1">positive</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">54.30</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">54.85</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">55.60</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">56.00</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">58.55</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">57.45</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">58.25</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Resistance to (A,Cp,K,S,H,O, Z,R); Susceptibility to (E)</td><td align="left" rowspan="1" colspan="1">S (Mon-Fri)+ M+E+T+ Et+Lz+ I+Clr+Clv</td><td align="left" rowspan="1" colspan="1">11/2013-11/2014</td><td align="center" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">59.40</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">36.4</td><td align="center" rowspan="1" colspan="1">positive</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">58.30</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">positive</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">60.90</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">positive</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">61.95</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">6.2</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">62.55</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">64.15</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">64.90</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">&lt; 6.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Resistance to (A,Cp,K,S,H,O,R); Susceptibility to (E.Z)</td><td align="left" rowspan="1" colspan="1">Cp (Mon-Fri)+M+ E+T+ Et+Lz+I+Clr+ Clv+Z</td><td align="left" rowspan="1" colspan="1">03/2014-03/2015</td><td align="center" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">36.30</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">91.0</td><td align="center" rowspan="1" colspan="1">positive</td><td align="center" rowspan="1" colspan="1">positive</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">40.75</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">59.1</td><td align="center" rowspan="1" colspan="1">positive</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">45.60</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">17.4</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.10</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">15.7</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">47.80</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">16.1</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">46.90</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">9.2</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">46.70</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">36.0</td><td align="center" rowspan="1" colspan="1">negative</td><td align="center" rowspan="1" colspan="1">negative</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CRP: C-reactive protein; A: amikacin; Cp: capreomycin; Clr: clarithromycin; Clv: clavulanate/amoxicillin; S: streptomycin; E: etambutol; Et: ethionamide; I: imipenem; H: isoniazid; K: kanamycin; Lz: linezolid; M: moxifloxacin; O: ofloxacin; Z: pyrazinamide; R: rifampin; T: terizidone; and Mon-Fri: from Monday to Friday. </p></fn></table-wrap-foot></table-wrap>
</p>
      <p>Chest X-rays (Figures 1, 2, and 3 for patients 1, 2, and 3, respectively), as well as laboratory test results at admission and after 1 year of treatment, can be found in the online supplement of the JBP (<ext-link ext-link-type="uri" xlink:href="http://www.jornaldepneumologia.com.br/detalhe_anexo.asp?id=43">http://www.jornaldepneumologia.com.br/detalhe_anexo.asp?id=43</ext-link>)</p>
      <p>
<supplementary-material content-type="local-data" id="suppl01"><media xlink:href="1806-3713-jbpneu-41-06-00554-suppl1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material>
</p>
      <sec>
        <title>Patient 1</title>
        <p>A 43-year-old male smoker (with a smoking history of 20 pack-years) presented to our institution. In addition to social drinking, he reported a history of cocaine use (he had not used it since 2011). He was unofficially employed as a car washer. He had previously been treated for tuberculosis but had not adhered to the prescribed treatment regimens. According to the patient, this was due to the fact that he was granted no social security benefit allowances for tuberculosis and had to work during the treatment period. His family income, in Brazilian reals (R$), was 800.00 (US$ 363.00). He lived in a two-bedroom household with his mother. He was admitted to HNGR on March 18, 2013. Treatment for XDR-TB was initiated on September 6, 2013. </p>
      </sec>
      <sec>
        <title>Patient 2</title>
        <p>A 41-year-old male smoker (with a smoking history of 20 pack-years) presented to our institution. He was a maintenance assistant. He reported a history of alcohol dependence (he had not consumed any alcohol since 2008) but no illicit drug use. He had been on sick leave while on treatment for tuberculosis, having been granted a social security benefit allowance. His family income was R$ 1,400.00 (US$ 437.00). He lived in a single room with his wife, a 1-year-old child, and two teenage children. He was admitted to HNGR on October 24, 2013. Treatment for XDR-TB was initiated on November 1, 2013. </p>
      </sec>
      <sec>
        <title>Patient 3</title>
        <p>A 25-year-old female smoker (with a smoking history of 5 pack-years) presented to our institution. She was unofficially employed as a clerk in a bakery. She reported social drinking but no illicit drug use. Her salary was R$ 725.00 (US$ 327.00). She had previously been treated for tuberculosis but had not adhered to the prescribed treatment regimens. According to the patient, this was due to the fact that she was granted no social security benefit allowances for tuberculosis and had to work during the treatment period. She lived in a three-bedroom household with three other people (a 5-year-old daughter, a brother, and her mother) and slept alone in one of the bedrooms. She had received home oxygen therapy in the period between December of 2013 and her admission to HNGR. She was hospitalized on February 10, 2014. Treatment for XDR-TB was initiated on March 10, 2014. </p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In the present study, we reported three cases of XDR-TB patients who had previously been treated for tuberculosis. The use of a treatment regimen based on the WHO guidelines in association with a new combination of antituberculosis drugs (imipenem and linezolid) resulted in clinical and bacteriological cure, as well as in significant radiological improvement. To our knowledge, our study is the first in Latin America and the second in the world to report the use of imipenem for the treatment of patients with XDR-TB, as well as being the first in the world to report the cases of three XDR-TB patients who were cured with the use of imipenem-linezolid. </p>
      <p>At HNGR, treatment is initiated after careful clinical and medication history taking. Smear microscopy is performed at the hospital. Cultures for Koch's bacillus and drug susceptibility testing are performed at the Adolfo Lutz Institute and repeated every two months. Laboratory tests are performed at the S&#xE3;o Paulo State University School of Pharmaceutical Sciences and repeated every three months. At admission, chest X-rays and CT scans are taken, the former being repeated every two months. The initial proposal is inpatient treatment for 24 months, depending on the clinical, bacteriological, and laboratory response. </p>
      <p>Both MDR-TB and XDR-TB are multifactorial and are caused by one or more of the following: inappropriate treatment regimens, inadequate drug doses, or inadequate treatment duration; mismanagement of antituberculosis drugs, affecting supply and quality; laboratories where resolution rates are low; addition of one or more drugs to a treatment regimen that has failed; treatment discontinuation or irregular medication use; and infection with primary MDR-TB strains.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
</p>
      <p>The chest X-rays taken at admission revealed serious pulmonary sequelae in patients 1 and 3, a finding that might be due to the fact that those patients had been treated for tuberculosis several times before, albeit erratically and, consequently, ineffectively. Patient 2 had received a basic treatment regimen under supervision. The fact that the treatment failed might be attributed to primary MDR-TB. </p>
      <p>Patients 1 and 2 received treatment with nine different drugs, and patient 3 received treatment with ten drugs, in accordance with the WHO guidelines for the treatment of MDR-TB (<xref ref-type="table" rid="t1">Table 1</xref>) and XDR-TB,<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> as well as having received drugs that susceptibility test results showed they were sensitive to. Before their hospitalization, our patients had alternately or inconsistently used group 1 drugs, group 2 drugs, group 3 drugs, and group 4 drugs (<xref ref-type="table" rid="t2">Table 2</xref>). Patient 1 was the only patient who had used a group 5 drug (clofazimine; <xref ref-type="table" rid="t2">Table 2</xref>). For patients with XDR-TB, there are few drug options to create an acceptable and effective treatment regimen.<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref> Our three patients received an injectable (group 2) drug and a next-generation fluoroquinolone (moxifloxacin). Despite relative contraindications in the WHO guidelines, streptomycin was given to patient 2 because the patient had received amikacin under supervision for approximately 20 months before hospital admission and because capreomycin was unavailable at the time. All patients received group 4 drugs (terizidone and ethionamide) and group 5 drugs (imipenem and linezolid). A case-control study showed the efficacy and tolerability of the meropenem-clavulanate/linezolid combination in the treatment of patients with MDR-TB or XDR-TB.<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref> A recent study showed the efficacy of ertapenem as an alternative for the treatment (including outpatient treatment) of MDR-TB.<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref> In the present study, clavulanate was used as an adjuvant to imipenem/cilastatin<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> and in combination with amoxicillin, given that clavulanate is not provided separately. Although the effect of clarithromycin on <italic>M </italic>. <italic>tuberculosis </italic> is uncertain, clarithromycin was used in all three patients because of its synergistic effect with linezolid.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref> According to the WHO guidelines,<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> ethambutol does not have a key role in the treatment of MDR-TB, even in cases of patients who are susceptible to it (e.g., patients 2 and 3 in the present study). Nevertheless, all three patients in the present study received ethambutol. Patient 3 was the only patient who received pyrazinamide, on the basis of susceptibility test results. </p>
      <p>After the first year of treatment, the proposed follow-up consisted of maintaining the use of injectable drugs for 18 months and the use of oral drugs for 24 months (<xref ref-type="table" rid="t1">Tables 1</xref> and <xref ref-type="table" rid="t6">
<sup>3</sup>
</xref>). At this writing, patients 1 and 2 had been discharged as cured, whereas patient 2 had had clinical, radiological, and bacteriological improvement. It is of note that none of the patients had adverse drug reactions. </p>
      <p>The pharmacological treatment of XDR-TB is costly. The Brazilian government spent approximately R$ 76,000.00 (US$ 30,000) per year on drugs alone for each of the patients included in the present study. A study conducted in South Africa showed that the treatment of one patient with XDR-TB costs US$ 26,392, which is four times higher than the treatment of one patient with MDR-TB (US$ 6,772) and 103 times higher than the treatment of one patient with tuberculosis that is susceptible to the basic treatment regimen (US$ 257).<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref> In addition, drug-resistant tuberculosis results in destruction of the lung parenchyma, which has an impact on patient quality of life and makes it extremely difficult to calculate post-discharge costs for patients and governments. </p>
      <p>In conclusion, governments must make every effort to prevent MDR-TB and XDR-TB. In extreme cases, such as those reported here, hospitalization is required in order to ensure an effective treatment for an adequate period of time.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn1" fn-type="supported-by">
        <p>Financial support: None.</p>
      </fn>
      <fn id="fn2" fn-type="other">
        <label>2</label>
        <p>Study carried out at Hospital Nestor Goulart Reis, Secretaria de Estado da Sa&#xFA;de do Estado de S&#xE3;o Paulo, Am&#xE9;rico Brasiliense (SP) Brasil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <source>Global tuberculosis report 2014</source>
          <year>2014</year>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Falzon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gandhi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Migliori</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Sotgiu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Holtz</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
          <article-title>Resistance to fluoroquinolones and second-line injectable drugs impact on multidrug-resistant TB outcomes</article-title>
          <source>Eur Respir J</source>
          <year>2013</year>
          <volume>42</volume>
          <issue>1</issue>
          <fpage>156</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00134712</pub-id>
          <pub-id pub-id-type="pmid">23100499</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Migliori</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Sotgiu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gandhi</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Falzon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>DeRiemer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Centis</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Drug resistance beyond extensively drug-resistant tuberculosis individual patient data meta-analysis</article-title>
          <source>Eur Respir J</source>
          <year>2013</year>
          <volume>42</volume>
          <issue>1</issue>
          <fpage>169</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00136312</pub-id>
          <pub-id pub-id-type="pmid">23060633</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pooran</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pieterson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Davids</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Theron</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dheda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>1</issue>
          <elocation-id/>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0054587</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vandeputte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>de Vries</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stillo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wanlin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nienhaus</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Costs of tuberculosis disease in the European Union a systematic analysis and cost calculation</article-title>
          <source>Eur Respir J</source>
          <year>2014</year>
          <volume>43</volume>
          <issue>2</issue>
          <fpage>554</fpage>
          <lpage>565</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00079413</pub-id>
          <pub-id pub-id-type="pmid">23949960</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jassal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bishai</surname>
              <given-names>WR</given-names>
            </name>
          </person-group>
          <article-title>Extensively drug-resistant tuberculosis</article-title>
          <source>Lancet Infect Dis</source>
          <year>2009</year>
          <volume>9</volume>
          <issue>1</issue>
          <fpage>19</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1016/S1473-3099(08)70260-3</pub-id>
          <pub-id pub-id-type="pmid">18990610</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Brasil. Minist&#xE9;rio da Sa&#xFA;de.Secretaria em Vigil&#xE2;ncia em Sa&#xFA;de. Departamento de Vigil&#xE2;ncia Epidemiol&#xF3;gica. Programa Nacional de Controle da Tuberculose</collab>
          </person-group>
          <source>Nota t&#xE9;cnica sobre as mudan&#xE7;as no tratamento da tuberculose no Brasil para adultos e adolescentes - Vers&#xE3;o 2</source>
          <year>2009</year>
          <publisher-loc>Bras&#xED;lia</publisher-loc>
          <publisher-name>Minist&#xE9;rio da Sa&#xFA;de</publisher-name>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zumla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chalaya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Centis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>D`Ambrosio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mwaba</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tuberculosis treatment and management--an update on treatment regimens.trials.new drugs.and adjunct therapies</article-title>
          <source>Lancet Respir Med</source>
          <year>2015</year>
          <volume>3</volume>
          <issue>3</issue>
          <fpage>220</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(15)00063-6</pub-id>
          <pub-id pub-id-type="pmid">25773212</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Falzon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jaramillo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sch&#xFC;nemann</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Arentz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bayona</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>WHO guidelines for the programmatic management of drug-resistant tuberculosis 2011 update</article-title>
          <source>Eur Respir J</source>
          <year>2011</year>
          <volume>38</volume>
          <issue>3</issue>
          <fpage>516</fpage>
          <lpage>528</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00073611</pub-id>
          <pub-id pub-id-type="pmid">21828024</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franke</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Appleton</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Mitnick</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Furin</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Bayona</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chalco</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence</article-title>
          <source>Clin Infect Dis</source>
          <year>2013</year>
          <volume>56</volume>
          <issue>6</issue>
          <fpage>770</fpage>
          <lpage>776</lpage>
          <pub-id pub-id-type="doi">10.1093/cid/cis1008</pub-id>
          <pub-id pub-id-type="pmid">23223591</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vel&#xE1;squez</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Becerra</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Gelmanova</surname>
              <given-names>IY</given-names>
            </name>
            <name>
              <surname>Pasechnikov</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Yedilbayev</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Improving outcomes for multidrug-resistant tuberculosis aggressive regimens prevent treatment failure and death</article-title>
          <source>Clin Infect Dis</source>
          <year>2014</year>
          <volume>59</volume>
          <issue>1</issue>
          <fpage>9</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1093/cid/ciu209</pub-id>
          <pub-id pub-id-type="pmid">24729493</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Lorenzo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Alffenaar</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Sotgiu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Centis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>D'Ambrosio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tiberi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB</article-title>
          <source>Eur Respir J</source>
          <year>2013</year>
          <volume>41</volume>
          <issue>6</issue>
          <fpage>1386</fpage>
          <lpage>1392</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00124312</pub-id>
          <pub-id pub-id-type="pmid">22997218</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tiberi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>D&#xB4;Ambrosio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>De Lorenzo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Viggiani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Centis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sotgiu</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ertapenem in the treatment of MDR-TB: first clinical experience</article-title>
          <source>Eur Respir J</source>
          <year>2015</year>
          <date-in-citation content-type="access-date" iso-8601-date="2015-11-19">2015 Nov 19</date-in-citation>
          <!--<pub-id pub-id-type="pii">ERJ-01278-2015</pub-id>-->
          <comment>Epub ahead of print</comment>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bolhuis</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>van Altena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>van Soolingen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>de Lange</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Uges</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>van der Werf</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients</article-title>
          <source>Eur Respir J</source>
          <year>2013</year>
          <volume>42</volume>
          <issue>6</issue>
          <fpage>1614</fpage>
          <lpage>1621</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00001913</pub-id>
          <pub-id pub-id-type="pmid">23520311</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="s1" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>O desafio do tratamento da tuberculose extensivamente resistente em um hospital de refer&#xEA;ncia no estado de S&#xE3;o Paulo: um relato de tr&#xEA;s casos</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Arbex</surname>
            <given-names>Marcos Abdo</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff8">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Siqueira</surname>
            <given-names>H&#xE9;lio Ribeiro de</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">
<sup>3</sup>
</xref>
          <xref ref-type="aff" rid="aff10">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>D'Ambrosio</surname>
            <given-names>Lia</given-names>
          </name>
          <xref ref-type="aff" rid="aff11">
<sup>5</sup>
</xref>
          <xref ref-type="aff" rid="aff12">
<sup>6</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Migliori</surname>
            <given-names>Giovanni Battista</given-names>
          </name>
          <xref ref-type="aff" rid="aff11">
<sup>5</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff7"><label>1</label>. Hospital Nestor Goulart Reis, Secretaria de Estado da Sa&#xFA;de do Estado de S&#xE3;o Paulo, Am&#xE9;rico Brasiliense (SP) Brasil.</aff>
      <aff id="aff8"><label>2</label>. Curso de Medicina, Centro Universit&#xE1;rio de Araraquara, Araraquara (SP) Brasil.</aff>
      <aff id="aff9"><label>3</label>. Disciplina de Pneumologia e Tisiologia, Faculdade de Ci&#xEA;ncias M&#xE9;dicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro (RJ) Brasil.</aff>
      <aff id="aff10"><label>4</label>. Ambulat&#xF3;rio de Tuberculose, Hospital Universit&#xE1;rio Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro (RJ) Brasil.</aff>
      <aff id="aff11"><label>5</label>. WHO Collaborating Centre for TB and Lung Diseases, Istituto Scientifico, Fondazione Salvatore Maugeri, Tradate, Italia.</aff>
      <aff id="aff12"><label>6</label>. Public Health Consulting Group, Lugano, Switzerland.</aff>
      <author-notes>
        <corresp id="c2">Endere&#xE7;o para correspond&#xEA;ncia: Marcos Abdo Arbex. Rua Volunt&#xE1;rios da P&#xE1;tria, 2104, CEP 14801-320, Araraquara, SP, Brasil. Tel.: 55 16 99714-2882. Fax: 55 16 3333-7788. E-mail: <email>arbexma@techs.com.br</email></corresp>
      </author-notes>
      <abstract>
        <title>RESUMO</title>
        <p>Relatamos aqui os casos de tr&#xEA;s pacientes portadores de tuberculose extensivamente resistente, internados em um hospital de refer&#xEA;ncia no estado de S&#xE3;o Paulo, e mostramos sua evolu&#xE7;&#xE3;o cl&#xED;nica, radiol&#xF3;gica e laboratorial pelo per&#xED;odo de um ano. O tratamento institu&#xED;do foi baseado nas diretrizes da Organiza&#xE7;&#xE3;o Mundial da Sa&#xFA;de, com a inclus&#xE3;o de uma nova proposta de uso de uma associa&#xE7;&#xE3;o de drogas antituberculose (linezolida e imipenem). Nos casos estudados, demonstrou-se o desafio de construir um esquema terap&#xEA;utico aceit&#xE1;vel e eficiente com drogas mais t&#xF3;xicas, mais dispendiosas e que foram utilizadas por per&#xED;odos mais prolongados. Mostramos tamb&#xE9;m o importante acr&#xE9;scimo nos custos do tratamento desses pacientes, com poss&#xED;veis impactos no sistema de sa&#xFA;de mesmo ap&#xF3;s a alta hospitalar. Ressaltamos que, em casos extremos como os apresentados neste estudo, a hospitaliza&#xE7;&#xE3;o em centros de refer&#xEA;ncia mostrou-se o caminho mais efetivo para oferecer tratamento adequado com possibilidade de cura. Em conclus&#xE3;o, todos os esfor&#xE7;os dos profissionais da sa&#xFA;de e do poder p&#xFA;blico devem ser direcionados a evitar casos de tuberculose multirresistente e extensivamente resistente. </p>
      </abstract>
      <kwd-group>
        <title>Descritores:</title>
        <kwd>Tuberculose resistente a m&#xFA;ltiplos medicamentos</kwd>
        <kwd>Tuberculose extensivamente resistente a drogas</kwd>
        <kwd>Antituberculosos</kwd>
        <kwd>Antibi&#xF3;ticos antituberculose</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>INTRODU&#xC7;&#xC3;O</title>
        <p>O expressivo aumento do n&#xFA;mero de casos de tuberculose multirresistente (TB-MDR, do ingl&#xEA;s <italic>multidrug-resistant </italic>) e de tuberculose extensivamente resistente (TB-XDR, do ingl&#xEA;s <italic>extensively drug-resistant </italic>) torna essas formas da doen&#xE7;a um grave problema de sa&#xFA;de p&#xFA;blica mundial. Dados recentes mostram que o n&#xFA;mero de casos de TB-MDR triplicou entre 2009 e 2013.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> Em 2013, 3,5% dos casos novos de tuberculose e 20,5% dos casos previamente tratados foram de TB-MDR. A TB-XDR respondeu por 9% dos casos de TB-MDR notificados em 100 pa&#xED;ses.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> A TB-MDR &#xE9; causada pelo <italic>Mycobacterium tuberculosis </italic> resistente &#xE0; rifampicina e &#xE0; isoniazida, enquanto, na TB-XDR, o bacilo apresenta resist&#xEA;ncia adicional a qualquer fluoroquinolona e a pelo menos um dos tr&#xEA;s medicamentos injet&#xE1;veis de segunda linha (amicacina, canamicina ou capreomicina).<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>-</sup>
<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref> O crescente reconhecimento de TB-MDR/XDR provocou o desenvolvimento de novas estrat&#xE9;gias terap&#xEA;uticas utilizando novas e antigas drogas tuberculost&#xE1;ticas. As drogas de primeira linha (mais efetivas), de segunda linha (menos efetivas, mais t&#xF3;xicas, menos eficazes e que demandam um per&#xED;odo mais prolongado de tratamento), e as consideradas de refor&#xE7;o (dependendo de sua efic&#xE1;cia e tolerabilidade) foram agrupadas pela Organiza&#xE7;&#xE3;o Mundial da Sa&#xFA;de (OMS) em cinco categorias. <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B5" ref-type="bibr">
<sup>5</sup>
</xref> A distribui&#xE7;&#xE3;o dessas drogas em categorias, assim como a recomenda&#xE7;&#xE3;o da OMS para sua utiliza&#xE7;&#xE3;o, est&#xE1; demonstrada na <xref ref-type="table" rid="t4">Tabela 1</xref>.</p>
        <p>
<table-wrap id="t4" orientation="portrait" position="float"><label>Tabela 1</label><caption><title>Grupos de drogas antituberculosas propostos pela Organiza&#xE7;&#xE3;o Mundial de Sa&#xFA;de e a recomenda&#xE7;&#xE3;o passo a passo para compor um regime de tratamento para pacientes com tuberculose multirresistente ou extensivamente resistente.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Grupos</th><th align="center" rowspan="1" colspan="1">Drogas</th><th align="center" rowspan="1" colspan="1">Passos</th><th align="center" rowspan="1" colspan="1">A&#xE7;&#xE3;o</th><th align="center" rowspan="1" colspan="1">Drogas a considerar</th><th align="center" rowspan="1" colspan="1">Notas</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Drogas de primeira linha v.o. &#x2022; Isoniazida &#x2022; Rifampicina &#x2022; Etambutol &#x2022; Pirazinamida &#x2022; Rifabutina &#x2022; Rifapentina</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Escolher uma droga injet&#xE1;vel (grupo 2) com base no teste de sensibilidade ou na hist&#xF3;ria minuciosa dos tratamentos pr&#xE9;vios.</td><td align="center" rowspan="1" colspan="1">Amicacina, capreomicina, canamicina</td><td align="center" rowspan="1" colspan="1">A estreptomicina geralmente n&#xE3;o &#xE9; utilizada pelo alto grau de resist&#xEA;ncia em pacientes portadores de TB-MDR.</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Drogas i.v. &#x2022; Estreptomicina &#x2022; Canamicina &#x2022; Amicacina &#x2022; Capreomicina</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Escolher uma fluoroquinolona de &#xFA;ltima gera&#xE7;&#xE3;o (grupo 3).</td><td align="center" rowspan="1" colspan="1">Levofloxacina, moxifloxacina</td><td align="center" rowspan="1" colspan="1">Se houver resist&#xEA;ncia a levofloxacina, utilizar moxifloxacina. Evitar o uso de moxifloxacina, se poss&#xED;vel, se utilizar bedaquilina.</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Fluoroquinolonas &#x2022; Levofloxacina &#x2022; Moxifloxacina &#x2022; Gatifloxacina</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Adicionar duas ou mais drogas do grupo 4.</td><td align="center" rowspan="1" colspan="1">Cicloserina, terizidona, &#xE1;cido para-aminossalic&#xED;lico, etionamida, protionamida</td><td align="center" rowspan="1" colspan="1">Etionamida/protionamida s&#xE3;o consideradas as drogas mais efetivas do grupo 4. Considerar a hist&#xF3;ria dos tratamentos anteriores, os efeitos colaterais e o custo. O teste de sensibilidade geralmente n&#xE3;o &#xE9; realizado para este grupo de drogas.</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Drogas de segunda linha v.o. &#x2022; Etionamida &#x2022; Protionamida &#x2022; Cicloserina &#x2022; Terizidona &#x2022; &#xC1;cido para-aminossalicilico &#x2022; Para-aminossalicilato de s&#xF3;dio</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Adicionar drogas do grupo 1.</td><td align="center" rowspan="1" colspan="1">Pirazinamida, etambutol</td><td align="center" rowspan="1" colspan="1">A pirazinamida &#xE9; comumente utilizada na maioria dos regimes. O etambutol &#xE9; utilizado dependendo do teste de sensibilidade.</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">F&#xE1;rmacos de refor&#xE7;o &#x2022; Linezolida &#x2022; Ertapenem &#x2022; Imipenem/cilastatina &#x2022; Meropenem &#x2022; Claritromicina &#x2022; Tioacetazona &#x2022; Amoxicilina/clavulanato &#x2022; Clofazimina &#x2022; Isoniazida em altas doses (a&#xE7;&#xE3;o modesta) &#x2022; Bedaquilina &#x2022; Delamanid</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Considerar a adi&#xE7;&#xE3;o das drogas do grupo 5 caso n&#xE3;o seja poss&#xED;vel utilizar 4 drogas efetivas dos grupos 2-3-4.</td><td align="center" rowspan="1" colspan="1">Bedaquilina, linezolida, clofazimina, amoxicilina/clavulanato, ertapenem, imipenem/cilastatina com clavulanato, meropenem com clavulanato, isoniazida em altas doses, claritromicina, tioacetazona</td><td align="center" rowspan="1" colspan="1">Caso haja necessidade de drogas deste grupo, &#xE9; poss&#xED;vel utilizar 2 ou mais drogas considerando que n&#xE3;o haja testes de sensibilidade padronizados para este grupo de medicamentos.</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>Adaptado da Organiza&#xE7;&#xE3;o Mundial de Sa&#xFA;de<sup>(1)</sup> e de Zumla et al.<sup>(8)</sup> TB-MDR: tuberculose multirresistente.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>O tratamento para a TB-MDR pode ser padronizado ou individualizado. Regimes padronizados s&#xE3;o sugeridos pelos &#xF3;rg&#xE3;os oficiais com base nos dados de sa&#xFA;de (por exemplo, padr&#xE3;o de resist&#xEA;ncia) de determinada regi&#xE3;o. <xref rid="B2" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>,</sup>
<xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref> No Brasil, o tratamento da TB-MDR &#xE9; padronizado pelo Minist&#xE9;rio da Sa&#xFA;de.<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref> A OMS<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> recomenda o tratamento da TB-MDR em duas fases: intensiva e de manuten&#xE7;&#xE3;o. A fase intensiva, com dura&#xE7;&#xE3;o de 8 meses, deve incluir no m&#xED;nimo quatro drogas potencialmente efetivas: uma droga injet&#xE1;vel (grupo 2), uma fluoroquinolona (grupo 3), uma droga oral (grupo 4) e um f&#xE1;rmaco de refor&#xE7;o (grupo 5). Na fase de manuten&#xE7;&#xE3;o, retira-se a droga injet&#xE1;vel, e as outras drogas devem ser mantidas por 12 meses ap&#xF3;s a negativa&#xE7;&#xE3;o da cultura do escarro. <xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref> Entretanto, alguns autores sugerem o tratamento pelo per&#xED;odo m&#xED;nimo de 20 meses. Estudos recentes mostraram que a fase de manuten&#xE7;&#xE3;o pelo per&#xED;odo de 18 meses ap&#xF3;s a negativa&#xE7;&#xE3;o da cultura previne a fal&#xEA;ncia, a recidiva e a mortalidade.<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>-</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</p>
        <p>Em rela&#xE7;&#xE3;o &#xE0; TB-XDR, o tratamento deve ser sempre individualmente delineado com base em uma minuciosa hist&#xF3;ria do tratamento antibacilar e nos padr&#xF5;es de resist&#xEA;ncia &#xE0;s drogas de primeira e segunda linha.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref> Para estes casos, a OMS<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> prop&#xF5;e cuidados especiais, entre os quais a utiliza&#xE7;&#xE3;o de pirazinamida e/ou algum outro f&#xE1;rmaco do grupo 1; a utiliza&#xE7;&#xE3;o de quinolonas de &#xFA;ltima gera&#xE7;&#xE3;o (moxifloxacina ou gatifloxacina) mesmo se o teste de sensibilidade mostrar resist&#xEA;ncia a levofloxacina e/ou ofloxacina; o uso do agente injet&#xE1;vel (aminoglicos&#xED;deo ou capreomicina) para qual a amostra bacteriol&#xF3;gica &#xE9; sens&#xED;vel, sempre que poss&#xED;vel, e sua extens&#xE3;o de uso por 12 meses ou mesmo por todo o tratamento; a utiliza&#xE7;&#xE3;o de dois ou mais agentes do grupo 5; e a utiliza&#xE7;&#xE3;o de todos os agentes do grupo 4 que n&#xE3;o foram prescritos extensivamente nos regimes pr&#xE9;vios ou ainda aqueles que forem considerados efetivos.</p>
        <p>O presente estudo teve como objetivo mostrar a evolu&#xE7;&#xE3;o no per&#xED;odo de 1 ano de tr&#xEA;s pacientes com TB-XDR internados no Hospital Nestor Goulart Reis (HNGR), localizado no munic&#xED;pio de Am&#xE9;rico Brasiliense (SP), que &#xE9; um hospital de refer&#xEA;ncia da Secret&#xE1;ria de Estado da Sa&#xFA;de do Estado de S&#xE3;o Paulo para o tratamento de TB-MDR/XDR que necessitam interna&#xE7;&#xE3;o.</p>
      </sec>
      <sec>
        <title>RELATO DE CASOS</title>
        <p>Relatamos abaixo os casos de tr&#xEA;s pacientes que foram internados e tratados na nossa institui&#xE7;&#xE3;o. Os tratamentos e os testes de sensibilidade anteriores &#xE0; interna&#xE7;&#xE3;o desses tr&#xEA;s pacientes (identificados como pacientes 1, 2 e 3) s&#xE3;o descritos na <xref ref-type="table" rid="t5">Tabela 2</xref>, enquanto tratamentos, testes de sensibilidade, evolu&#xE7;&#xE3;o do peso corporal e resultados de baciloscopia, cultura para bacilo de Koch, VHS e prote&#xED;na C reativa ap&#xF3;s a interna&#xE7;&#xE3;o est&#xE3;o descritos na <xref ref-type="table" rid="t6">Tabela 3</xref>.</p>
        <p>
<table-wrap id="t5" orientation="portrait" position="float"><label>Tabela 2</label><caption><title>Local e regime de tratamento, teste de sensibilidade, drogas utilizadas e desfechos anteriores &#xE0; interna&#xE7;&#xE3;o no Hospital Nestor Goulart Reis dos tr&#xEA;s casos relatados.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="2"/><col span="2"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Tipo de regime</th><th align="center" rowspan="2" colspan="1">Teste de sensibilidade</th><th align="center" rowspan="2" colspan="1">Per&#xED;odo (m&#xEA;s/ano)</th><th align="center" colspan="2" rowspan="1">Regime adotado</th><th align="center" colspan="2" rowspan="1">Desfecho</th></tr><tr><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">H</th><th align="center" rowspan="1" colspan="1">Z</th><th align="center" rowspan="1" colspan="1">E</th><th align="center" rowspan="1" colspan="1">S</th><th align="center" rowspan="1" colspan="1">Et</th><th align="center" rowspan="1" colspan="1">O</th><th align="center" rowspan="1" colspan="1">T</th><th align="center" rowspan="1" colspan="1">C</th><th align="center" rowspan="1" colspan="1">A</th><th align="center" rowspan="1" colspan="1">L</th></tr><tr><th align="center" rowspan="1" colspan="1">Paciente 1</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,E,S)</td><td align="left" rowspan="1" colspan="1">05/2001-11/2001</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Fal&#xEA;ncia</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,E,Z,S)</td><td align="left" rowspan="1" colspan="1">01/2003-07/2003</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Abandono</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,Z)</td><td align="left" rowspan="1" colspan="1">09/2005-09/2007</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Abandono</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,Z); Sen (E,S)</td><td align="left" rowspan="1" colspan="1">11/2007-07/2008</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Abandono</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,E,Z)</td><td align="left" rowspan="1" colspan="1">08/2008-09/2010</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Abandono</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,E,Z,S)</td><td align="left" rowspan="1" colspan="1">06/2011-10/2011</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Encaminhado para interna&#xE7;&#xE3;o (Sanatorinhos, Campos do Jord&#xE3;o)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hosp</td><td align="left" rowspan="1" colspan="1">Res (A,C,K,S,E,H,O,Z,R)</td><td align="left" rowspan="1" colspan="1">10/2011-03/2013</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Alta disciplinar</td></tr><tr><td align="left" rowspan="1" colspan="1">Hosp (HNGR)</td><td align="left" rowspan="1" colspan="1">Res (A,C,S,H,O,Z,R); Sen (E)</td><td align="left" rowspan="1" colspan="1">03/2013-08/2013</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Fal&#xEA;ncia</td></tr><tr><td align="center" rowspan="1" colspan="1">Paciente 2</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">03/2011-10/2011</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Fal&#xEA;ncia</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,Z,O); Sen (A,K,Cp,S,E)</td><td align="left" rowspan="1" colspan="1">03/2012-10/2013</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Fal&#xEA;ncia</td></tr><tr><td align="center" rowspan="1" colspan="1">Paciente 3</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">01/2006-05/2006</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Abandono</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H); Sen (Z,E,S,Et)</td><td align="left" rowspan="1" colspan="1">06/2006-06/2007</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Abandono</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H); Sen (Z,E,S,Et)</td><td align="left" rowspan="1" colspan="1">08/2007-07/2009</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Cura</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H); Sen (Z,E,S)</td><td align="left" rowspan="1" colspan="1">09/2009-04/2010</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Fal&#xEA;ncia</td></tr><tr><td align="left" rowspan="1" colspan="1">Hosp (Sanatorinhos, Campos do Jord&#xE3;o) ou Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,S); Sen (Z,E)</td><td align="left" rowspan="1" colspan="1">04/2010-03/2012</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Fal&#xEA;ncia</td></tr><tr><td align="left" rowspan="1" colspan="1">Amb</td><td align="left" rowspan="1" colspan="1">Res (R,H,S); Sen (Z,E)</td><td align="left" rowspan="1" colspan="1">02/2013-02/2014</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">Fal&#xEA;ncia</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p>R: rifampicina; H: isoniazida; Z: pirazinamida; E: etambutol; S: estreptomicina; Et: etionamida; O: ofloxacina; T: terizidona; C: clofazimina; A: amicacina; L: levofloxacina; K: canamicina; Cp: capreomicina; Amb: ambulatorial; Res: resistente; Sen: sens&#xED;vel; Hosp: hospitalar; e HNGR: Hospital Nestor Goulart Reis.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>
<table-wrap id="t6" orientation="portrait" position="float"><label>Tabela 3</label><caption><title>Resultados de teste de sensibilidade, tratamento realizado, evolu&#xE7;&#xE3;o do peso, VHS, prote&#xED;na C reativa, baciloscopia e cultura para bacilo de Koch em um ano de tratamento dos tr&#xEA;s pacientes estudados.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Paciente</th><th align="center" rowspan="1" colspan="1">Teste de sensibilidade</th><th align="center" rowspan="1" colspan="1">Tratamento</th><th align="center" rowspan="1" colspan="1">Dura&#xE7;&#xE3;o</th><th align="center" rowspan="1" colspan="1">M&#xEA;s</th><th align="center" rowspan="1" colspan="1">Peso, kg</th><th align="center" rowspan="1" colspan="1">VHS, mm/h</th><th align="center" rowspan="1" colspan="1">PCR, mg/l</th><th align="center" rowspan="1" colspan="1">Cultura</th><th align="center" rowspan="1" colspan="1">Baciloscopia</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Res (A,Cp,K, S,E,H,O,Z,R)</td><td align="left" rowspan="1" colspan="1">A (2-6 f) +M+E+T+Et+ Lz+I+Clr+Clv</td><td align="left" rowspan="1" colspan="1">09/2013-09/2014</td><td align="center" rowspan="1" colspan="1">Inicial</td><td align="center" rowspan="1" colspan="1">55,00</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">31,6</td><td align="center" rowspan="1" colspan="1">positiva</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">54,15</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">6,7</td><td align="center" rowspan="1" colspan="1">positiva</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">54,30</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">54,85</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">55,60</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">56,00</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">58,55</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">57,45</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">Negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">58,25</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Res (A,Cp,K,S,H, O,Z,R); Sen (E)</td><td align="left" rowspan="1" colspan="1">S (2-6 f) +M+E+T+Et+ Lz+I+Clr+Clv</td><td align="left" rowspan="1" colspan="1">11/2013-11/2014</td><td align="center" rowspan="1" colspan="1">Inicial</td><td align="center" rowspan="1" colspan="1">59,40</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">36,4</td><td align="center" rowspan="1" colspan="1">positiva</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">58,30</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">positiva</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">60,90</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">positiva</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">61,95</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">6,2</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">62,55</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">64,15</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">64,90</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">&lt; 6,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Res (A,Cp,K,S,H, O,R); Sen (E,Z)</td><td align="left" rowspan="1" colspan="1">Cp (2-6 f) +M+E+T+Et+ Lz+I+Clr+Clv+Z</td><td align="left" rowspan="1" colspan="1">03/2014-03/2015</td><td align="center" rowspan="1" colspan="1">Inicial</td><td align="center" rowspan="1" colspan="1">36,30</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">91,0</td><td align="center" rowspan="1" colspan="1">positiva</td><td align="center" rowspan="1" colspan="1">positiva</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">40,75</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">59,1</td><td align="center" rowspan="1" colspan="1">positiva</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">45,60</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">17,4</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46,10</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">15,7</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">47,80</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">16,1</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">46,90</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">9,2</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">46,70</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">36,0</td><td align="center" rowspan="1" colspan="1">negativa</td><td align="center" rowspan="1" colspan="1">negativa</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p>PCR: prote&#xED;na C reativa; Res: resistente; Sen: sens&#xED;vel; A: amicacina; Cp: capreomicina; Clr: claritromicina; Clv: clavulanato/amoxicilina; S: estreptomicina; E: etambutol; Et: etionamida; I: imipenem; H: isoniazida; K: canamicina; Lz: linezolida; M: moxifloxacina; O: ofloxacina; Z: pirazinamida; R: rifampicina; T: terizidona; e 2-6 f: medica&#xE7;&#xE3;o tomada pelo paciente de segunda &#xE0; sexta-feira.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>As radiografias de t&#xF3;rax (Figuras 1, 2 e 3 em rela&#xE7;&#xE3;o aos pacientes 1, 2 e 3, respectivamente) e os resultados de outros exames laboratoriais na admiss&#xE3;o e ap&#xF3;s 1 ano de tratamento est&#xE3;o dispon&#xED;veis no suplemento on-line no site do JBP (<ext-link ext-link-type="uri" xlink:href="http://www.jornaldepneumologia.com.br/detalhe_anexo.asp?id=43">http://www.jornaldepneumologia.com.br/detalhe_anexo.asp?id=43</ext-link>).</p>
        <p>
<supplementary-material content-type="local-data" id="suppl02"><media xlink:href="1806-3713-jbpneu-41-06-00554-suppl2.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material>
</p>
        <sec>
          <title>Paciente 1</title>
          <p>Homem de 43 anos, tabagista (20 anos-ma&#xE7;o), alcoolismo social e usu&#xE1;rio de coca&#xED;na at&#xE9; 2011. Lavador de ve&#xED;culos, sem registro. Referia n&#xE3;o ades&#xE3;o ao tratamento por n&#xE3;o receber aux&#xED;lio-doen&#xE7;a e ser obrigado a trabalhar durante os diversos tratamentos pr&#xE9;vios para tuberculose. Tinha renda familiar de R$ 800,00 (US$ 363,00). Residia em domicilio com dois quartos, onde morava com a m&#xE3;e. Foi internado em 18/03/2013. O in&#xED;cio do tratamento para TB-XDR ocorreu em 06/09/2013.</p>
        </sec>
        <sec>
          <title>Paciente 2 </title>
          <p>Homem de 41 anos, tabagista (20 anos-ma&#xE7;o), dependente de &#xE1;lcool at&#xE9; 2008, negava uso de drogas il&#xED;citas e era assistente de manuten&#xE7;&#xE3;o. Esteve em licen&#xE7;a m&#xE9;dica recebendo aux&#xED;lio-doen&#xE7;a durante os tratamentos ambulatoriais pr&#xE9;vios. Sua renda familiar era de R$ 1.400,00 (US$ 437,00). Residia em domicilio com c&#xF4;modo &#xFA;nico, onde morava com a esposa, uma crian&#xE7;a de 1 ano de idade e dois filhos adolescentes. Foi internado em 24/10/2013. O in&#xED;cio do tratamento para TB-XDR ocorreu em 01/11/2013.</p>
        </sec>
        <sec>
          <title>Paciente 3</title>
          <p>Mulher de 25 anos, tabagista (5 anos-ma&#xE7;o), etilista social, negava uso de drogas il&#xED;citas e era balconista em uma padaria. Seu sal&#xE1;rio era de R$ 725,00 (US$ 327,00), sem registro. Declarava apresentar m&#xE1; ades&#xE3;o ao tratamento por n&#xE3;o ter aux&#xED;lio-doen&#xE7;a e ser obrigada a trabalhar durante os diversos tratamentos anteriores. Residia em domicilio de tr&#xEA;s quartos com mais tr&#xEA;s pessoas (uma filha de 5 anos, um irm&#xE3;o e sua m&#xE3;e) e dormia sozinha em um dos quartos. Utilizara oxig&#xEA;nio domiciliar entre dezembro de 2013 e a interna&#xE7;&#xE3;o no HNGR. Foi internada em 10/02/2014. O in&#xED;cio do tratamento para TB-XDR ocorreu em 10/03/2014.</p>
        </sec>
      </sec>
      <sec>
        <title>DISCUSS&#xC3;O</title>
        <p>No presente estudo, relatamos tr&#xEA;s casos graves de TB-XDR, com diversos tratamentos pr&#xE9;vios, demonstrando que a utiliza&#xE7;&#xE3;o de um regime de drogas baseado nas diretrizes da OMS e com uma nova proposta de associa&#xE7;&#xE3;o de drogas antituberculose (linezolida e imipenem) levou a cura cl&#xED;nica e bacteriol&#xF3;gica e importante melhora radiol&#xF3;gica dos pacientes. &#xC0; luz do nosso conhecimento, este &#xE9; o primeiro relato de casos na Am&#xE9;rica Latina e o segundo em termos globais sobre a utiliza&#xE7;&#xE3;o do imipenem para o tratamento de pacientes portadores de TB-XDR, assim como o primeiro relato a n&#xED;vel mundial sobre a cura de pacientes TB-XDR com a associa&#xE7;&#xE3;o imipenem e linezolida.</p>
        <p>No HNGR, o tratamento &#xE9; iniciado ap&#xF3;s um minucioso levantamento da hist&#xF3;ria cl&#xED;nica e medicamentosa. A baciloscopia &#xE9; realizada no pr&#xF3;prio hospital. As culturas para bacilo de Koch e os testes de sensibilidade s&#xE3;o realizados no Instituto Adolfo Lutz e repetidos bimestralmente. Os exames laboratoriais s&#xE3;o realizados na Faculdade de Ci&#xEA;ncias Farmac&#xEA;uticas da Universidade Estadual Paulista e repetidos trimestralmente. &#xC0; interna&#xE7;&#xE3;o, s&#xE3;o realizadas radiografias e TCs de t&#xF3;rax, sendo as primeiras repetidas bimestralmente. A proposta inicial ao paciente &#xE9; de tratamento hospitalar por 24 meses, dependendo da resposta cl&#xED;nica, bacteriol&#xF3;gica e laboratorial.</p>
        <p>A TB-MDR/XDR &#xE9; multifatorial, podendo ocorrer por um ou mais dos seguintes fatores: administra&#xE7;&#xE3;o de tuberculost&#xE1;ticos feita pelos servi&#xE7;os de sa&#xFA;de com esquemas ou doses inadequadas ou com esquemas por per&#xED;odos demasiadamente curtos; m&#xE1; gest&#xE3;o na oferta e na qualidade das drogas; laborat&#xF3;rios com capacidade de resolutividade prec&#xE1;ria; adi&#xE7;&#xE3;o de uma ou mais drogas a um esquema j&#xE1; falido; pacientes que interrompem e/ou utilizam os medicamentos de forma irregular; e pacientes que adquirem a doen&#xE7;a atrav&#xE9;s de uma cepa primariamente multirresistente.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
</p>
        <p>O fato de os pacientes 1 e 3 terem sido submetidos a diversos tratamentos pr&#xE9;vios de forma irregular e, consequentemente, n&#xE3;o efetivos, pode ter contribu&#xED;do para as graves sequelas pulmonares observadas nas radiografias de t&#xF3;rax &#xE0; interna&#xE7;&#xE3;o. O paciente 2 fez tratamento com um esquema b&#xE1;sico, de forma supervisionada, e o desfecho foi fal&#xEA;ncia, o que poderia ser explicado por uma cepa de TB-MDR prim&#xE1;ria.</p>
        <p>Utilizamos nove drogas diferentes para o tratamento dos pacientes 1 e 2 e dez drogas para o paciente 3, em acordo com a orienta&#xE7;&#xE3;o da OMS para o tratamento de TB-MDR (<xref ref-type="table" rid="t4">Tabela 1</xref>) e as orienta&#xE7;&#xF5;es especiais da mesma para a TB-XDR,<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> al&#xE9;m de f&#xE1;rmacos aos quais as cepas encontradas se mostraram sens&#xED;veis no teste de sensibilidade. Os pacientes utilizaram, previamente &#xE0; interna&#xE7;&#xE3;o e de forma alternada e/ou inconsistente, drogas dos grupos 1 a 4 (<xref ref-type="table" rid="t5">Tabela 2</xref>). Somente o paciente 1 utilizou uma droga do grupo 5 (clofazimina; <xref ref-type="table" rid="t5">Tabela 2</xref>). Quando tratamos pacientes portadores de TB-XDR, h&#xE1; poucas alternativas medicamentosas para construir um regime de tratamento aceit&#xE1;vel e eficiente.<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref> Utilizamos para os tr&#xEA;s pacientes uma droga injet&#xE1;vel (grupo 2) e uma fluoroquinolona de ultima gera&#xE7;&#xE3;o (moxifloxacina). Apesar da contraindica&#xE7;&#xE3;o relativa da OMS, optou-se pelo uso da estreptomicina no paciente 2, considerando que o mesmo j&#xE1; havia utilizado a amicacina sob supervis&#xE3;o por aproximadamente 20 meses antes da interna&#xE7;&#xE3;o e que n&#xE3;o havia disponibilidade de capreomicina na &#xE9;poca. Todos receberam as drogas dos grupos 4 (terizidona e etionamida) e 5 (imipenem e linezolida). Um estudo caso-controle pr&#xE9;vio mostrou a efetividade e a tolerabilidade da associa&#xE7;&#xE3;o meropenem+clavulanato/linezolida no tratamento de pacientes com TB-MDR/XDR.<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref> Um estudo recente mostrou a efetividade do ertapenem como alternativa para esse tratamento mesmo ambulatoriamente.<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref> Associamos o clavulanato como um agente adjuvante ao imipenem/cilastatina<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> e sempre associado &#xE0; amoxicilina, considerando que o mesmo n&#xE3;o &#xE9; disponibilizado isoladamente. A claritromicina, apesar de sua atividade incerta sobre o <italic>M. tuberculosis </italic>, foi utilizada em todos os pacientes pelo seu efeito sin&#xE9;rgico &#xE0; efetividade da linezolida.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref> Utilizamos o etambutol em todos os pacientes, inclusive no paciente 1, apesar de a OMS<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> n&#xE3;o considerar essa droga como um f&#xE1;rmaco-chave nos regimes terap&#xEA;uticos para TB-MDR, mesmo quando existe sensibilidade &#xE0; droga (pacientes 2 e 3). Optamos pelo uso da pirazinamida somente para o paciente 3, em acordo com o teste de sensibilidade.</p>
        <p>A proposta de seguimento ap&#xF3;s o primeiro ano foi para manter as medica&#xE7;&#xF5;es injet&#xE1;veis por 18 meses e as orais por 24 meses (<xref ref-type="table" rid="t4">Tabelas 1</xref> e <xref ref-type="table" rid="t6">
<sup>3</sup>
</xref>). At&#xE9; o momento, os pacientes 1 e 2 tiveram alta por cura, e o paciente 3 mant&#xE9;m melhora cl&#xED;nica, radiol&#xF3;gica e bacteriol&#xF3;gica. Cabe ressaltar que nenhum paciente apresentou quaisquer efeitos adversos &#xE0;s medica&#xE7;&#xF5;es utilizadas.</p>
        <p>O custo da terap&#xEA;utica medicamentosa para pacientes com TB-XDR traz um grande impacto financeiro. O valor anual despendido pelo poder p&#xFA;blico somente com medicamentos para cada paciente inclu&#xED;do no presente estudo foi de, aproximadamente, R$ 76.000,00 (US$ 30.000). Um estudo realizado na &#xC1;frica do Sul mostrou que o tratamento de um paciente portador de TB-XDR tem um custo de US$ 26.392, quatro vezes maior que o do tratamento de um paciente portador de TB-MDR (US$ 6.772) e 103 vezes maior que o de um paciente portador de tuberculose sens&#xED;vel ao esquema b&#xE1;sico (US$ 257).<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref> Al&#xE9;m disso, temos de considerar a grande destrui&#xE7;&#xE3;o do par&#xEA;nquima pulmonar, que n&#xE3;o somente impacta a qualidade de vida do paciente, mas torna extremamente dif&#xED;cil o c&#xE1;lculo dos custos posteriores &#xE0; alta hospitalar, tanto para o paciente como para o poder p&#xFA;blico.</p>
        <p>Em conclus&#xE3;o, s&#xE3;o necess&#xE1;rios todos os esfor&#xE7;os do poder p&#xFA;blico no sentido de evitar a TB-MDR/XDR. Em casos extremos como os apresentados no presente estudo, &#xE9; necess&#xE1;rio considerar a interna&#xE7;&#xE3;o para garantir um tratamento efetivo por um per&#xED;odo de tempo adequado.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn id="fn3" fn-type="supported-by">
          <p>Apoio financeiro: Nenhum.</p>
        </fn>
        <fn id="fn4" fn-type="other">
          <label>4</label>
          <p>Trabalho realizado no Hospital Nestor Goulart Reis, Secretaria de Estado da Sa&#xFA;de do Estado de S&#xE3;o Paulo, Am&#xE9;rico Brasiliense (SP) Brasil.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
</pmc-articleset>
